Gehlert D R, Gackenheimer S L, Schober D A
Central Nervous System Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
Neurochem Int. 1992 Jul;21(1):45-67. doi: 10.1016/0197-0186(92)90067-2.
Subtypes of the neuropeptide Y (NPY) receptor in the rat brain were identified by the use of the selective Y-1 analog, [Leu34-Pro34] NPY. In rat brain homogenate binding studies, [Leu31-Pro34] NPY was found to produce a partial inhibition of 100 pM 125I-labeled peptide YY (PYY) binding with a plateau at 50-1000 nM [Leu31-Pro34] NPY resulting in a 70% inhibition of binding. The C-terminal fragment NPY 13-36, a putative Y-2 agonist, exhibited very little selectivity in rat brain homogenates. Scatchard analysis of 125I-labeled PYY binding to rat brain homogenate yielded biphasic plots with Kd values of 40 and 610 pM. Inclusion of 100 nM [Leu31-Pro34] NPY was found to eliminate the low affinity component of 125I-labeled PYY binding leaving a single, high affinity binding site with a Kd of 68 pM. In autoradiographic studies, displacement curves indicated that [Leu31-Pro34] NPY completely inhibited binding in the cerebral cortex with little effect on the binding in the hypothalamus. On the other hand NPY 13-36 inhibited binding in the hypothalamus at low concentrations but required higher concentrations to inhibit binding in the cerebral cortex. Other brain regions such as the hippocampus, appeared to contain both subtypes. Subsequent to these studies, a quantitative autoradiographic map was conducted using 50-100 pM 125I-labeled PYY in the presence and absence of [Leu31-Pro34] NPY which produced a selective displacement of binding in certain distinct brain regions. These areas included the cerebral cortex, certain thalamic nuclei and brainstem while ligand binding was retained in other brain regions including the zona lateralis of the substantia nigra, lateral septum, nucleus of the solitary tract and the hippocampus. Numerous brain regions appeared to contain both receptor subtypes. Therefore, the Y-1 and Y-2 receptor subtypes exhibited a somewhat distinct distribution in the brain. In addition, 125I-labeled PYY appears to label the Y-2 receptor with relatively higher affinity when compared to the Y-1 receptor.
通过使用选择性Y-1类似物[Leu34-Pro34]神经肽Y(NPY),鉴定了大鼠脑中NPY受体的亚型。在大鼠脑匀浆结合研究中,发现[Leu31-Pro34]NPY对100 pM 125I标记的肽YY(PYY)结合产生部分抑制作用,在50 - 1000 nM [Leu31-Pro34]NPY时达到平台期,导致70%的结合抑制。C末端片段NPY 13 - 36是一种假定的Y-2激动剂,在大鼠脑匀浆中表现出很少的选择性。对125I标记的PYY与大鼠脑匀浆结合的Scatchard分析产生双相图,Kd值分别为40和610 pM。发现加入100 nM [Leu31-Pro34]NPY可消除125I标记的PYY结合的低亲和力成分,留下一个单一的高亲和力结合位点,Kd为68 pM。在放射自显影研究中,置换曲线表明[Leu31-Pro34]NPY完全抑制大脑皮质中的结合,对下丘脑结合的影响很小。另一方面,NPY 13 - 36在低浓度时抑制下丘脑的结合,但需要更高浓度才能抑制大脑皮质中的结合。其他脑区如海马体,似乎同时含有这两种亚型。在这些研究之后,使用50 - 100 pM 125I标记的PYY,在有和没有[Leu31-Pro34]NPY的情况下进行了定量放射自显影图谱分析,[Leu31-Pro34]NPY在某些不同的脑区产生了选择性结合置换。这些区域包括大脑皮质、某些丘脑核和脑干,而配体结合保留在其他脑区,包括黑质外侧带、外侧隔、孤束核和海马体。许多脑区似乎同时含有这两种受体亚型。因此,Y-1和Y-2受体亚型在脑中表现出 somewhat distinct分布。此外,与Y-1受体相比,125I标记的PYY似乎以相对较高的亲和力标记Y-2受体。 (注:“somewhat distinct”直译为“有点不同”,此处保留英文是因为在医学语境中可能需要根据具体情况进一步理解其含义)